Here are the S-3 shelf registrations from Beyond Air, Inc. (XAIR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow XAIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAIR filings page.
Beyond Air, Inc. is registering for resale up to 5,417,538 shares of common stock for selling stockholders. The Shares consist of 167,011 issued shares plus shares issuable from Pre-Funded, Series A, and Series B Warrants. Beyond Air is not selling shares in this offering and will not receive proceeds from resales, though it may receive cash if warrants are exercised, which it expects to use for general working capital.
The Shares stem from a July 29, 2026 securities purchase agreement and a July 31, 2026 private placement that generated $10.2 million in gross proceeds at prices near market. Pre-Funded Warrants are exercisable at $0.0001 per share; Series A and B Warrants at $5.51 per share, subject to 4.99%–19.99% beneficial ownership limits. Common stock outstanding was 755,549 shares as of July 28, 2026, and would be 6,173,087 shares if all new warrants are exercised.
The company completed a 1-for-20 reverse stock split effective July 13, 2026 to address prior Nasdaq bid-price noncompliance and is now under a one-year Discretionary Panel Monitor. Beyond Air is a commercial-stage company marketing its FDA- and CE-marked LungFit® PH nitric oxide system and developing additional NO-based respiratory, oncology and neurology programs.
Beyond Air, Inc. has filed an S-3 shelf registration to allow existing investors to resell common stock and shares issuable from previously issued warrants. The filing covers 524,990 outstanding common shares, plus additional shares issuable from pre-funded warrants and common warrants.
The pre-funded warrants are exercisable at $0.0001 per share, and the common warrants are exercisable at $1.147 per share through January 16, 2031. Beyond Air will not receive proceeds from stockholder resales, but would receive cash if holders exercise these warrants. Shares outstanding were 10,529,344 as of January 22, 2026, and would be 17,865,990 if all warrant shares in this filing are issued.